AbbVie Reports Full-Year and Fourth-Quarter 2025 Financial Results

Rhea-AI Summary

AbbVie (NYSE:ABBV) reported full-year 2025 net revenues of $61.160 billion (+8.6% reported, +8.5% operational) and full-year GAAP diluted EPS of $2.36 (adjusted diluted EPS $10.00), which include an unfavorable $2.76 per-share impact from acquired IPR&D and milestones. Fourth-quarter revenues were $16.618 billion (+10.0% reported) with adjusted diluted EPS of $2.71 and GAAP EPS of $1.02. AbbVie provided 2026 adjusted diluted EPS guidance of $14.37–$14.57, excluding any acquired IPR&D and milestones impact.

Key portfolio highlights: Skyrizi $17.562B, Rinvoq $8.304B, Humira $4.540B; 2025 saw multiple regulatory submissions and an FDA approval for Epkinly in follicular lymphoma.

Positive

• Full-year net revenues of $61.160B, +8.6% reported
• Immunology portfolio net revenues $30.406B, +14.0% reported
• Skyrizi net revenues $17.562B, strong growth
• 2026 adjusted diluted EPS guidance of $14.37–$14.57 (excludes IPR&D impacts)

Negative

• Full-year GAAP diluted EPS of $2.36, down 1.3%
• 2025 included $2.76 per-share unfavorable acquired IPR&D and milestones expense
• Humira full-year net revenues $4.540B, continuing decline post-LOE

Key Figures

FY 2025 GAAP diluted EPS: $2.36 FY 2025 adjusted EPS: $10.00 FY 2025 net revenues: $61.160 billion +5 more

8 metrics

FY 2025 GAAP diluted EPS $2.36 Full-year 2025; decreased 1.3%

FY 2025 adjusted EPS $10.00 Full-year 2025; decreased 1.2%

FY 2025 net revenues $61.160 billion Full-year 2025; up 8.6% reported, 8.5% operational

FY 2025 immunology revenues $30.406 billion Full-year 2025; up 14.0% reported

Q4 2025 net revenues $16.618 billion Fourth quarter 2025; up 10.0% reported

Q4 2025 GAAP EPS $1.02 Fourth quarter 2025 diluted EPS

2026 EPS guidance $14.37–$14.57 Full-year 2026 adjusted diluted EPS guidance (excl. IPR&D/milestones)

U.S. investment commitment $100 billion Planned U.S. R&D and capital investments over next decade

Market Reality Check

Price: $225.56 Vol: Volume 5,242,393 vs 20-da...

normal vol

$225.56 Last Close

Volume Volume 5,242,393 vs 20-day average 7,343,898 (relative volume 0.71) ahead of this earnings release. normal

Technical Price 225.56 trades above 200-day MA at 208.93, near the upper end of the 52-week range.

Peers on Argus

Large-cap pharma peers were mixed: LLY appeared in momentum scanners moving up 8...

1 Up 1 Down

Large-cap pharma peers were mixed: LLY appeared in momentum scanners moving up 8.62%, while NVO showed a -4.00% move down. With ABBV essentially flat ahead of earnings, moves do not indicate a unified sector rotation.

Common Catalyst Earnings season for large-cap pharma, with at least one major peer (LLY) also reporting results.

Previous Earnings Reports

5 past events · Latest: Oct 31 (Negative)

Same Type Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Oct 31	Q3 2025 earnings	Negative	-4.5%	Large IPR&D charges drove sharp EPS drop and weaker adjusted EPS.
Jul 31	Q2 2025 earnings	Positive	-0.1%	Strong revenue and EPS growth with raised 2025 guidance despite IPR&D impact.
Apr 25	Q1 2025 earnings	Positive	+3.1%	Robust revenue growth in immunology and higher EPS guidance range.
Jan 31	FY 2024 results	Positive	+4.7%	Growing key portfolios and 2025 EPS guidance supported a strong reaction.
Oct 30	Q3 2024 earnings	Positive	+6.4%	Revenue growth, higher 2024 EPS guidance, and dividend increase boosted shares.

Pattern Detected

Earnings releases often coincided with positive price reactions when guidance was raised, though one quarter with heavy IPR&D charges saw a negative move.

Recent Company History

Over the last five earnings cycles, AbbVie consistently highlighted growing immunology and neuroscience portfolios, frequent guidance raises, and significant IPR&D investments. Events on Jan 31, 2025 and Oct 30, 2024 showed strong revenue growth and guidance increases with positive share reactions. The Q3 2025 report on Oct 31, 2025 featured large IPR&D charges, weaker EPS and a negative move. Today’s full-year 2025 update continues the theme of portfolio-driven growth alongside sizable R&D-related expenses and forward EPS guidance.

Historical Comparison

earnings

+1.9 %

Average Historical Move

Historical Analysis

Recent earnings updates often paired strong portfolio growth with guidance raises and IPR&D charges, with average moves of 1.92% on these events.

Typical Pattern

Across the last five earnings releases, AbbVie emphasized accelerating Skyrizi and Rinvoq sales, expanding neuroscience revenues, and repeatedly lifting EPS guidance, while absorbing sizable acquired IPR&D expenses that periodically pressured GAAP EPS.

Market Pulse Summary

This announcement details strong 2025 revenue growth, led by immunology and neuroscience, alongside ...

Analysis

This announcement details strong 2025 revenue growth, led by immunology and neuroscience, alongside sizable acquired IPR&D expenses that weigh on GAAP EPS. Full-year net revenues reached $61.160 billion, with immunology at $30.406 billion, while adjusted EPS was $10.00. AbbVie also issued 2026 EPS guidance of $14.37–$14.57 and highlighted multiple regulatory and clinical milestones. Investors may watch future earnings for how recurring R&D charges, key product growth, and execution against this guidance evolve.

Key Terms

ipr&d, phase 3, pfs, overall survival, +4 more

8 terms

ipr&d financial

"These Results Include an Unfavorable Impact of $2.76 Per Share Related to 2025 Acquired IPR&D"

In-process research and development (IPR&D) is the value a buyer assigns to ongoing drug, product, or technology projects acquired before they are finished. It matters to investors because this intangible asset represents potential future revenue and carries high uncertainty—like purchasing a half-built house that could become a valuable home or require expensive work—and it affects a buyer’s reported assets, future write-downs, and earnings when projects fail or succeed.

phase 3 medical

"data from the Phase 3 Viti-Up clinical trials, in which Rinvoq achieved the co-primary endpoints"

Phase 3 is the late-stage clinical testing step for a new drug or medical treatment, where the product is given to large groups of patients to confirm effectiveness, monitor side effects, and compare it to standard care. Successful Phase 3 results are often the final scientific hurdle before regulators decide on approval and market launch—like passing a final exam before graduation—and can sharply change a company's valuation and future revenue prospects.

pfs medical

"demonstrated significantly superior progression-free survival (PFS) and overall response (OR) rates"

Progression-free survival (PFS) is a clinical-trial measure that records how long, on average, patients live without their disease getting worse after starting a treatment. For investors, PFS acts like a stopwatch of a drug’s effectiveness: longer PFS can signal meaningful patient benefit, improve chances of regulatory approval or label strength, and raise a drug’s commercial value, while shorter or unchanged PFS can weigh on a company’s prospects.

overall survival medical

"The study did not demonstrate a statistically significant improvement in overall survival (OS)."

Overall survival is the average or median length of time patients remain alive after starting a treatment or entering a clinical study, measured regardless of cause of death. Investors care because it is a clear, hard measure of a therapy’s real-world benefit — like timing how long a new battery actually runs — and strong improvements in overall survival can drive regulatory approval, market adoption and revenue potential.

bispecific antibody medical

"a novel investigational Programmed Cell Death-1 (PD-1)/Vascular Endothelial Growth Factor (VEGF)-targeted bispecific antibody."

A bispecific antibody is a specially designed protein that can attach to two different targets at the same time. Think of it as a custom-made connector that brings two things together—such as a disease cell and an immune system component—helping the body fight illnesses more effectively. For investors, understanding bispecific antibodies is important because they represent innovative therapies that could lead to new treatments and potentially lucrative market opportunities.

chemoimmunotherapy medical

"evaluating Epkinly compared to investigator's choice of chemoimmunotherapy in adult patients"

Chemoimmunotherapy is a cancer treatment approach that combines drugs that directly kill tumor cells with medicines that boost or guide the patient’s immune system to recognize and attack cancer. For investors, it matters because combining these two approaches can change clinical trial outcomes, regulatory paths, potential sales and pricing, and the risk/reward profile of drug candidates much like adding a second player to a team can improve performance but also complicate strategy and costs.

pd-1 medical

"Programmed Cell Death-1 (PD-1)/Vascular Endothelial Growth Factor (VEGF)-targeted bispecific antibody."

PD-1 is a protein found on certain immune cells that acts like a brake, signaling the immune system to slow down and avoid damaging healthy tissue. Drugs that block PD-1 release that brake so immune cells can better attack cancer cells; because such therapies can produce large clinical benefits, regulatory approvals, trial outcomes, pricing and market uptake for PD-1 drugs can materially affect a drugmaker’s prospects and investor returns.

vegf medical

"Programmed Cell Death-1 (PD-1)/Vascular Endothelial Growth Factor (VEGF)-targeted bispecific antibody."

Vascular endothelial growth factor (VEGF) is a naturally occurring protein that signals the body to grow new blood vessels, like a fertilizer prompts plants to sprout. It matters to investors because drugs that block or mimic VEGF can dramatically change outcomes for cancers and eye diseases, making them major drivers of clinical trial results, regulatory approvals, market value and future revenue potential for biopharma companies.

AI-generated analysis. Not financial advice.

• Reports Full-Year Diluted EPS of $2.36 on a GAAP Basis, a Decrease of 1.3 Percent; Adjusted Diluted EPS of $10.00, a Decrease of 1.2 Percent; These Results Include an Unfavorable Impact of $2.76 Per Share Related to 2025 Acquired IPR&D and Milestones Expense 
   
• Delivers Full-Year Net Revenues of $61.160 Billion, an Increase of 8.6 Percent on a Reported Basis and 8.5 Percent on an Operational Basis 
   
• Full-Year Global Net Revenues from the Immunology Portfolio Were $30.406 Billion, an Increase of 14.0 Percent on a Reported Basis, or 13.9 Percent on an Operational Basis; Global Skyrizi Net Revenues Were $17.562 Billion; Global Rinvoq Net Revenues Were $8.304 Billion; Global Humira Net Revenues Were $4.540 Billion
   
• Full-Year Global Net Revenues from the Neuroscience Portfolio Were $10.767 Billion, an Increase of 19.6 Percent on a Reported Basis, or 19.4 Percent on an Operational Basis; Global Vraylar Net Revenues Were $3.621 Billion; Global Botox Therapeutic Net Revenues Were $3.769 Billion; Combined Global Ubrelvy and Qulipta Net Revenues were $2.307 Billion
   
• Full-Year Global Net Revenues from the Oncology Portfolio Were $6.655 Billion, an Increase of 1.5 Percent on a Reported Basis, or 1.4 Percent on an Operational Basis; Global Imbruvica Net Revenues Were $2.869 Billion; Global Venclexta Net Revenues Were $2.792 Billion; Global Elahere Net Revenues Were $690 Million
   
• Full-Year Global Net Revenues from the Aesthetics Portfolio Were $4.860 Billion, a Decrease of 6.1 Percent on a Reported Basis, or 5.9 Percent on an Operational Basis; Global Botox Cosmetic Net Revenues Were $2.602 Billion; Global Juvederm Net Revenues Were $993 Million
   
• Reports Fourth-Quarter Diluted EPS of $1.02 on a GAAP Basis; Adjusted Diluted EPS of $2.71; These Results Include an Unfavorable Impact of $0.71 Per Share Related to Fourth-Quarter 2025 Acquired IPR&D and Milestones Expense
   
• Delivers Fourth-Quarter Net Revenues of $16.618 Billion, an Increase of 10.0 Percent on a Reported Basis and 9.5 Percent on an Operational Basis
   
• Provides 2026 Adjusted Diluted EPS Guidance Range of $14.37 to $14.57; Excludes Any Unfavorable Impact Related to Acquired IPR&D and Milestones Expense

NORTH CHICAGO, Ill., Feb. 4, 2026 /PRNewswire/ -- AbbVie (NYSE:ABBV) announced financial results for the fourth quarter and full year ended December 31, 2025.

"2025 was another outstanding year for AbbVie. We delivered record net sales in just the second full year following the U.S. Humira loss of exclusivity, underscoring the strength of our diversified growth platform. We also advanced promising new treatments for patients while enhancing the breadth and depth of our pipeline with strategic investments," said Robert A. Michael, chairman and chief executive officer, AbbVie. "Based on our strong fundamentals, we expect another year of robust growth in 2026. This momentum combined with our investments in innovation position AbbVie for long-term success."

Fourth-Quarter Results

• Worldwide net revenues were $16.618 billion, an increase of 10.0 percent on a reported basis, or 9.5 percent on an operational basis.
   
• Global net revenues from the immunology portfolio were $8.626 billion, an increase of 18.3 percent on a reported basis, or 17.7 percent on an operational basis.
  • Global Skyrizi net revenues were $5.006 billion, an increase of 32.5 percent on a reported basis, or 31.9 percent on an operational basis.
  • Global Rinvoq net revenues were $2.374 billion, an increase of 29.5 percent on a reported basis, or 28.6 percent on an operational basis.
  • Global Humira net revenues were $1.246 billion, a decrease 25.9 percent on a reported basis, or 26.1 percent on an operational basis.
     
• Global net revenues from the neuroscience portfolio were $2.961 billion, an increase of 17.9 percent on a reported basis, or 17.3 percent on an operational basis.
  • Global Vraylar net revenues were $1.022 billion, an increase of 10.5 percent.
  • Global Botox Therapeutic net revenues were $990 million, an increase of 13.4 percent on a reported basis, or 13.0 percent on an operational basis.
  • Global Ubrelvy net revenues were $339 million, an increase of 12.0 percent.
  • Global Qulipta net revenues were $288 million, an increase of 42.6 percent on a reported basis, or 41.8 percent on an operational basis.
     
• Global net revenues from the oncology portfolio were $1.664 billion, a decrease of 1.5 percent on a reported basis, or 2.5 percent on an operational basis.
  • Global Imbruvica net revenues were $671 million, a decrease of 20.8 percent.
  • Global Venclexta net revenues were $710 million, an increase of 8.6 percent on a reported basis, or 6.4 percent on an operational basis.
  • Global Elahere net revenues were $182 million, an increase of 22.6 percent on a reported basis, or 21.3 percent on an operational basis.
     
• Global net revenues from the aesthetics portfolio were $1.286 billion, a decrease of 0.9 percent on a reported basis, or 1.2 percent on an operational basis.
  • Global Botox Cosmetic net revenues were $717 million, an increase of 4.2 percent on a reported basis, or 3.8 percent on an operational basis.
  • Global Juvederm net revenues were $249 million, a decrease of 10.7 percent on a reported basis, or 10.8 percent on an operational basis.
    
    
• On a GAAP basis, the gross margin ratio in the fourth quarter was 72.6 percent. The adjusted gross margin ratio was 83.6 percent.
   
• On a GAAP basis, selling, general and administrative (SG&A) expense was 23.4 percent of net revenues. The adjusted SG&A expense was 22.3 percent of net revenues.
   
• On a GAAP basis, research and development (R&D) expense was 15.5 percent of net revenues. The adjusted R&D expense was 15.4 percent of net revenues.
   
• Acquired IPR&D and milestones expense was 7.6 percent of net revenues.
   
• On a GAAP basis, the operating margin ratio in the fourth quarter was 27.3 percent. The adjusted operating margin ratio was 38.3 percent.
   
• Net interest expense was $655 million.
   
• On a GAAP basis, the tax rate in the quarter was 32.0 percent. The adjusted tax rate was 18.3 percent.
   
• Diluted EPS in the fourth quarter was $1.02 on a GAAP basis. Adjusted diluted EPS, excluding specified items, was $2.71. These results include an unfavorable impact of $0.71 per share related to acquired IPR&D and milestones expense.

^{Note: "Operational" comparisons are presented at constant currency rates that reflect comparative local currency net revenues at the prior year's foreign exchange rates.} 

Recent Events

• AbbVie announced a voluntary agreement with the Trump administration to further advance access and affordability for Americans while protecting and investing in U.S. pharmaceutical innovation. Under the agreement, AbbVie will provide low prices in Medicaid, and expand affordable, direct-to-patient offerings for treatments used by millions of Americans. The company will also commit $100 billion in U.S. R&D and capital investments, including manufacturing, over the next decade. This three-year agreement provides AbbVie with exemption from tariffs and future pricing mandates.
   
• AbbVie announced it submitted applications for a new indication to the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) for Rinvoq (upadacitinib) in the treatment of adult and adolescent patients living with non-segmental vitiligo. The submissions are supported by data from the Phase 3 Viti-Up clinical trials, in which Rinvoq achieved the co-primary endpoints of 50 percent improvement in total body re-pigmentation (T-VASI 50) and 75 percent improvement in facial re-pigmentation (F-VASI 75) from baseline at week 48. If approved, Rinvoq will be the first systemic treatment for patients with vitiligo, addressing important treatment needs for those living with the chronic, unpredictable autoimmune disease.
   
• AbbVie announced it submitted an application to the EMA for expanded use of Aquipta (atogepant) for the acute treatment of adults with migraine. The submission was supported by data from the pivotal Phase 3 ECLIPSE study, evaluating the safety, efficacy and tolerability of Aquipta versus placebo for the acute treatment of migraine in adults. The study met its primary and key secondary endpoints, with Aquipta demonstrating superiority in pain freedom and freedom from the most bothersome migraine symptom two hours after treatment of the first migraine attack. Study results were shared as a late-breaking presentation at the European Headache Congress.
   
• AbbVie announced the FDA approval of Epkinly (epcoritamab) in combination with rituximab and lenalidomide (R²) for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL). The approval is based on results from the Phase 3 EPCORE FL-1 study in which Epkinly with R² demonstrated significantly superior progression-free survival (PFS) and overall response (OR) rates compared to standard of care R², with approximately three out of four patients achieving a complete response (CR). This approval marks the third indication for Epkinly and first FDA approval for a bispecific combination therapy in lymphoma. Epkinly is being co-developed by AbbVie and Genmab.
   
• AbbVie announced topline results from the Phase 3 EPCORE DLBCL-1 trial evaluating Epkinly compared to investigator's choice of chemoimmunotherapy in adult patients with R/R diffuse large B-cell lymphoma (DLBCL). The study demonstrated an improvement in PFS and improvements were observed in CR rates, duration of response and time to next treatment among patients treated with Epkinly. The study did not demonstrate a statistically significant improvement in overall survival (OS). Based on the topline results from the trial, AbbVie along with partner Genmab will engage global regulatory authorities to discuss next steps.
   
• AbbVie and RemeGen announced an exclusive licensing agreement for the development, manufacturing and commercialization of RC148, a novel investigational Programmed Cell Death-1 (PD-1)/Vascular Endothelial Growth Factor (VEGF)-targeted bispecific antibody. RC148 is currently being developed by RemeGen as a monotherapy and in combination regimens across multiple advanced solid tumors including certain lung cancers. This transaction further strengthens AbbVie's diverse oncology portfolio and may offer new opportunities to explore combination regimens with AbbVie's antibody-drug conjugates (ADCs) such as investigational Temab-A (telisotuzumab adizutecan), across multiple solid tumors with high unmet need.
   
• AbbVie and West Pharmaceutical Services announced a definitive agreement for AbbVie to acquire a device manufacturing facility in Tempe, Arizona and associated intellectual property from West. The acquisition will support production of AbbVie's current and next-generation immunology and neuroscience medicines.

Full-Year 2026 Outlook

AbbVie is issuing its adjusted diluted EPS guidance for the full-year 2026 of $14.37 to $14.57. The company's 2026 adjusted diluted EPS guidance excludes any impact from acquired IPR&D and milestones that may be incurred during 2026, as both cannot be reliably forecasted.

About AbbVie

AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology, neuroscience and oncology – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X and YouTube.

Conference Call

AbbVie will host an investor conference call today at 8:00 a.m. Central Time to discuss our fourth-quarter performance. The call will be webcast through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the call will be available after 11:00 a.m. Central Time.

Non-GAAP Financial Results

Financial results for 2025 and 2024 are presented on both a reported and a non-GAAP basis. Reported results were prepared in accordance with generally accepted accounting principles in the United States (GAAP) and include all revenue and expenses recognized during the period. Non-GAAP results adjust for certain non-cash items and for factors that are unusual or unpredictable, and exclude those costs, expenses, and other specified items presented in the reconciliation tables later in this release. AbbVie's management believes non-GAAP financial measures provide useful information to investors regarding AbbVie's results of operations and assist management, analysts, and investors in evaluating the performance of the business. Non-GAAP financial measures should be considered in addition to, and not as a substitute for, measures of financial performance prepared in accordance with GAAP.

Forward-Looking Statements

Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations applicable to our industry, the impact of global macroeconomic factors, such as economic downturns or uncertainty, international conflict, trade disputes and tariffs, and other uncertainties and risks associated with global business operations. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2024 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its Quarterly Reports on Form 10-Q and in other documents that AbbVie subsequently files with the Securities and Exchange Commission that update, supplement or supersede such information. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

Media:	Investors:
Gabby Tarbert	Liz Shea
(224) 244-0111	(847) 935-2211
	Todd Bosse
	(847) 936-1182
	Jeffrey Byrne
	(847) 938-2923

 

AbbVie Inc. Key Product Revenues Quarter Ended December 31, 2025 (Unaudited)
							% Change vs. 4Q24
	Net Revenues (in millions)						Reported						Operationala
	U.S.		Int'l.		Total		U.S.		Int'l.		Total		Int'l.		Total
NET REVENUES	$  12,794		$  3,824		$  16,618		9.0 %		13.5 %		10.0 %		11.0 %		9.5 %
Immunology	6,961		1,665		8,626		17.9		19.7		18.3		16.8		17.7
Skyrizi	4,355		651		5,006		31.5		39.8		32.5		35.1		31.9
Rinvoq	1,709		665		2,374		26.9		36.4		29.5		33.2		28.6
Humira	897		349		1,246		(27.9)		(20.3)		(25.9)		(21.0)		(26.1)
Neuroscience	2,572		389		2,961		16.3		30.3		17.9		25.6		17.3
Vraylar	1,020		2		1,022		10.5		21.7		10.5		24.5		10.5
Botox Therapeutic	828		162		990		13.5		13.1		13.4		10.7		13.0
Ubrelvy	332		7		339		12.3		(3.7)		12.0		(3.0)		12.0
Qulipta	245		43		288		30.9		>100.0		42.6		>100.0		41.8
Vyalev	86		97		183		>100.0		>100.0		>100.0		>100.0		>100.0
Duodopa	17		75		92		(31.6)		(10.4)		(15.1)		(14.9)		(18.6)
Other Neuroscience	44		3		47		(13.9)		(20.1)		(14.4)		(19.0)		(14.3)
Oncology	997		667		1,664		(9.6)		13.6		(1.5)		10.8		(2.5)
Imbruvicab	469		202		671		(25.0)		(9.0)		(20.8)		(9.0)		(20.8)
Venclexta	332		378		710		6.2		10.8		8.6		6.6		6.4
Elahere	154		28		182		5.0		>100.0		22.6		>100.0		21.3
Epkinlyc	22		59		81		23.8		>100.0		>100.0		>100.0		>100.0
Other Oncology	20		—		20		n/m		n/m		n/m		n/m		n/m
Aesthetics	811		475		1,286		(3.3)		3.3		(0.9)		2.5		(1.2)
Botox Cosmetic	420		297		717		(2.1)		14.7		4.2		13.5		3.8
Juvederm Collection	107		142		249		(11.0)		(10.5)		(10.7)		(10.7)		(10.8)
Other Aesthetics	284		36		320		(1.8)		(14.5)		(3.4)		(15.0)		(3.5)
Eye Care	286		294		580		(19.7)		1.6		(10.1)		(0.4)		(11.0)
Ozurdex	32		96		128		(10.4)		14.1		6.9		10.4		4.3
Lumigan/Ganfort	47		57		104		(19.0)		(6.6)		(12.6)		(9.1)		(13.9)
Alphagan/Combigan	18		36		54		(54.8)		(4.5)		(30.5)		(5.4)		(30.9)
Other Eye Care	189		105		294		(14.9)		(1.5)		(10.5)		(2.3)		(10.8)
Other Key Products	711		173		884		(5.1)		5.3		(3.2)		1.3		(3.9)
Mavyret	163		161		324		17.9		4.9		11.0		0.8		8.9
Creon	385		—		385		(0.8)		n/m		(0.8)		n/m		(0.8)
Linzess/Constella	163		12		175		(26.8)		12.1		(25.1)		9.0		(25.2)

a	"Operational" comparisons are presented at constant currency rates that reflect comparative local currency net revenues at the prior year's foreign exchange rates.
b	Reflects profit sharing for Imbruvica international revenues.
c	Epkinly U.S. revenues reflect profit sharing. International revenues reflect product revenues as well as profit sharing from certain international territories.
n/m = not meaningful

 

AbbVie Inc. Key Product Revenues Twelve Months Ended December 31, 2025 (Unaudited)
							% Change vs. 12M24
	Net Revenues (in millions)						Reported					Operationala
	U.S.		Int'l.		Total		U.S.		Int'l.		Total		Int'l.		Total
NET REVENUES	$  46,603		$  14,557		$  61,160		8.3 %		9.4 %		8.6 %		9.2 %		8.5 %
Immunology	24,204		6,202		30,406		12.7		19.4		14.0		18.8		13.9
Skyrizi	15,202		2,360		17,562		50.7		44.6		49.9		43.0		49.7
Rinvoq	5,940		2,364		8,304		39.5		38.0		39.1		37.1		38.8
Humira	3,062		1,478		4,540		(57.1)		(20.2)		(49.5)		(19.5)		(49.4)
Neuroscience	9,340		1,427		10,767		18.1		30.7		19.6		29.3		19.4
Vraylar	3,612		9		3,621		10.8		33.3		10.8		36.8		10.8
Botox Therapeutic	3,151		618		3,769		16.0		9.3		14.8		9.9		14.9
Ubrelvy	1,239		32		1,271		26.3		28.6		26.4		30.7		26.5
Qulipta	906		130		1,036		44.1		>100.0		57.3		>100.0		56.8
Vyalev	167		315		482		>100.0		>100.0		>100.0		>100.0		>100.0
Duodopa	73		308		381		(23.7)		(12.3)		(14.8)		(14.1)		(16.2)
Other Neuroscience	192		15		207		(13.9)		(0.4)		(13.0)		2.8		(12.8)
Oncology	4,080		2,575		6,655		(3.3)		10.3		1.5		9.9		1.4
Imbruvicab	2,048		821		2,869		(16.4)		(8.6)		(14.3)		(8.6)		(14.3)
Venclexta	1,306		1,486		2,792		5.9		10.2		8.1		9.8		7.9
Elahere	607		83		690		27.2		>100.0		44.0		>100.0		43.4
Epkinlyc	86		185		271		42.3		>100.0		85.5		>100.0		85.0
Other Oncology	33		—		33		n/m		n/m		n/m		n/m		n/m
Aesthetics	2,990		1,870		4,860		(8.5)		(2.0)		(6.1)		(1.5)		(5.9)
Botox Cosmetic	1,504		1,098		2,602		(10.5)		5.7		(4.3)		6.2		(4.1)
Juvederm Collection	385		608		993		(18.0)		(14.1)		(15.6)		(13.6)		(15.3)
Other Aesthetics	1,101		164		1,265		(1.5)		1.8		(1.1)		2.7		(1.0)
Eye Care	954		1,155		2,109		(10.2)		(2.0)		(5.9)		(1.2)		(5.5)
Ozurdex	124		369		493		(10.1)		3.7		(0.2)		3.0		(0.7)
Lumigan/Ganfort	189		221		410		1.2		(8.7)		(4.4)		(8.3)		(4.2)
Alphagan/Combigan	53		144		197		(43.3)		(6.3)		(20.4)		(4.6)		(19.4)
Other Eye Care	588		421		1,009		(8.7)		(1.4)		(5.8)		0.5		(5.0)
Other Key Products	3,011		725		3,736		4.0		(3.8)		2.4		(4.8)		2.2
Mavyret	635		682		1,317		6.7		(4.7)		0.4		(5.7)		(0.2)
Creon	1,512		—		1,512		9.3		n/m		9.3		n/m		9.3
Linzess/Constella	864		43		907		(5.7)		13.6		(4.9)		13.3		(4.9)

a	"Operational" comparisons are presented at constant currency rates that reflect comparative local currency net revenues at the prior year's foreign exchange rates.
b	Reflects profit sharing for Imbruvica international revenues.
c	Epkinly U.S. revenues reflect profit sharing. International revenues reflect product revenues as well as profit sharing from certain international territories.
n/m = not meaningful

 

AbbVie Inc. Consolidated Statements of Earnings (Unaudited)
(in millions, except per share data)	Fourth Quarter Ended December 31				Twelve Months Ended December 31
	2025		2024		2025		2024
Net revenues	$       16,618		$       15,102		$       61,160		$       56,334
Cost of products sold	4,552		4,396		18,204		16,904
Selling, general and administrative	3,895		3,855		14,010		14,752
Research and development	2,579		6,774		9,096		12,791
Acquired IPR&D and milestones	1,265		1,574		5,016		2,757
Other operating income	(217)		(7)		(241)		(7)
Total operating costs and expenses	12,074		16,592		46,085		47,197
Operating earnings (loss)	4,544		(1,490)		15,075		9,137
Interest expense, net	655		610		2,627		2,160
Net foreign exchange loss	11		19		58		21
Other expense, net	1,210		150		5,793		3,240
Earnings (loss) before income tax expense	2,668		(2,269)		6,597		3,716
Income tax expense (benefit)	853		(2,246)		2,364		(570)
Net earnings (loss)	1,815		(23)		4,233		4,286
Net earnings (loss) attributable to noncontrolling interest	(1)		(1)		7		8
Net earnings (loss) attributable to AbbVie Inc.	$          1,816		$              (22)		$          4,226		$          4,278
Diluted earnings (loss) per share attributable to AbbVie Inc.	$            1.02		$           (0.02)		$            2.36		$            2.39
Adjusted diluted earnings per sharea	$            2.71		$            2.16		$          10.00		$          10.12
Weighted-average diluted shares outstanding	1,774		1,769		1,773		1,773
Adjusted weighted-average diluted shares outstandinga	1,774		1,773		1,773		1,773

a

Refer to the Reconciliation of GAAP Reported to Non-GAAP Adjusted Information for further details. Weighted-average diluted shares outstanding includes the effect of dilutive securities. Due to the GAAP net loss in the fourth quarter ended December 31, 2024, certain shares issuable under stock-based compensation plans that were dilutive on a non-GAAP basis were excluded from the computation of GAAP diluted EPS because the effects would have been antidilutive.

 

AbbVie Inc. Reconciliation of GAAP Reported to Non-GAAP Adjusted Information (Unaudited)
1.     Specified items impacted results as follows:
	Quarter Ended December 31, 2025
(in millions, except per share data)	Earnings				Diluted
	Pre-tax		After-taxa		EPS
As reported (GAAP)	$              2,668		$              1,816		$                1.02
Adjusted for specified items:
Intangible asset amortization	1,784		1,500		0.85
Change in fair value of contingent consideration	1,406		1,368		0.77
Other	51		146		0.07
As adjusted (non-GAAP)	$              5,909		$              4,830		$                2.71
a Represents net earnings attributable to AbbVie Inc. Specified items reflect the impact of applicable statutory tax rates.
Reported GAAP earnings and adjusted non-GAAP earnings for the three months ended December 31, 2025 included acquired IPR&D  and milestones expense of $1.3 billion on a pre-tax and after-tax basis, representing an unfavorable impact of $0.71 to both diluted  EPS and adjusted diluted EPS.

 

2.     The impact of the specified items by line item was as follows:
	Quarter Ended December 31, 2025
(in millions)	Cost of products sold		SG&A		R&D		Other operating income		Other expense, net
As reported (GAAP)	$    4,552		$    3,895		$    2,579		$       (217)		$    1,210
Adjusted for specified items:
Intangible asset amortization	(1,784)		—		—		—		—
Change in fair value of contingent consideration	—		—		—		—		(1,406)
Other	(42)		(190)		(16)		217		(20)
As adjusted (non-GAAP)	$    2,726		$    3,705		$    2,563		$           —		$      (216)

 

3.     The adjusted tax rate for the fourth quarter of 2025 was 18.3 percent, as detailed below:
	Quarter Ended December 31, 2025
(dollars in millions)	Pre-tax earnings		Income taxes		Tax rate
As reported (GAAP)	$             2,668		$                853		32.0 %
Specified items	3,241		227		7.0 %
As adjusted (non-GAAP)	$             5,909		$             1,080		18.3 %

 

AbbVie Inc. Reconciliation of GAAP Reported to Non-GAAP Adjusted Information (Unaudited)
1.     Specified items impacted results as follows:
	Quarter Ended December 31, 2024
(in millions, except per share data)	Earnings (Loss)				Diluted
	Pre-tax		After-taxa		EPS
As reported (GAAP)	$            (2,269)		$                 (22)		$              (0.02)
Adjusted for specified items:
Intangible asset amortization	1,896		1,607		0.90
Intangible asset impairment	4,476		3,512		1.98
Change in fair value of contingent consideration	279		271		0.15
Litigation matters	173		136		0.08
Income tax items	—		(1,869)		(1.05)
Other	258		209		0.12
As adjusted (non-GAAP)	$              4,813		$              3,844		$                2.16
a Represents net earnings (loss) attributable to AbbVie Inc. Specified items reflect the impact of applicable statutory tax rates.
Intangible asset impairment reflects a partial after-tax impairment charge of $3.5 billion related to the emraclidine intangible asset acquired as part of the Cerevel Therapeutics acquisition. Income tax items primarily reflect an income tax benefit related to the settlement of income tax examinations, partially offset by changes in income tax reserves.
Reported GAAP earnings and adjusted non-GAAP earnings for the three months ended December 31, 2024 included acquired IPR&D  and milestones expense of $1.6 billion on a pre-tax and after-tax basis, representing an unfavorable impact of $0.88 to both diluted EPS and adjusted diluted EPS.

 

2.     The impact of the specified items by line item was as follows:
	Quarter Ended December 31, 2024
(in millions)	Cost of products sold		SG&A		R&D		Other operating income		Other expense, net
As reported (GAAP)	$     4,396		$     3,855		$     6,774		$           (7)		$        150
Adjusted for specified items:
Intangible asset amortization	(1,896)		—		—		—		—
Intangible asset impairment	—		—		(4,476)		—		—
Change in fair value of contingent consideration	—		—		—		—		(279)
Litigation matters	—		(173)		—		—		—
Other	(47)		(121)		(25)		7		(72)
As adjusted (non-GAAP)	$     2,453		$     3,561		$     2,273		$           —		$      (201)

 

3.     The adjusted tax rate for the fourth quarter of 2024 was 20.2 percent, as detailed below:
	Quarter Ended December 31, 2024
(dollars in millions)	Pre-tax earnings (loss)		Income taxes		Tax rate
As reported (GAAP)	$            (2,269)		$            (2,246)		99.0 %
Specified items	7,082		3,216		45.4 %
As adjusted (non-GAAP)	$             4,813		$                970		20.2 %

 

AbbVie Inc. Reconciliation of GAAP Reported to Non-GAAP Adjusted Information (Unaudited)
1.     Specified items impacted results as follows:
	Twelve Months Ended December 31, 2025
(in millions, except per share data)	Earnings				Diluted
	Pre-tax		After-taxa		EPS
As reported (GAAP)	$              6,597		$              4,226		$                2.36
Adjusted for specified items:
Intangible asset amortization	7,377		6,221		3.50
Intangible asset impairment	847		701		0.39
Acquisition and integration costs	276		262		0.15
Change in fair value of contingent consideration	6,495		6,309		3.56
Other	100		65		0.04
As adjusted (non-GAAP)	$           21,692		$           17,784		$              10.00
a Represents net earnings attributable to AbbVie Inc. Specified items reflect the impact of applicable statutory tax rates.
Intangible asset impairment reflects impairment charges of $847 million related to the Resonic and Durysta intangible assets. Acquisition and integration costs primarily reflect costs related to the Capstan Therapeutics acquisition.
Reported GAAP earnings and adjusted non-GAAP earnings for the twelve months ended December 31, 2025 included acquired IPR&D and milestones expense of $5.0 billion on a pre-tax and $4.9 billion on an after-tax basis, representing an unfavorable impact of $2.76 to both diluted EPS and adjusted diluted EPS.

 

2.     The impact of the specified items by line item was as follows:
	Twelve Months Ended December 31, 2025
(in millions)	Cost of products sold		SG&A		R&D		Other operating income		Other expense, net
As reported (GAAP)	$  18,204		$  14,010		$    9,096		$      (241)		$    5,793
Adjusted for specified items:
Intangible asset amortization	(7,377)		—		—		—		—
Intangible asset impairment	(847)		—		—		—		—
Acquisition and integration costs	(15)		(172)		(89)		—		—
Change in fair value of contingent consideration	—		—		—		—		(6,495)
Other	(163)		(202)		(22)		241		46
As adjusted (non-GAAP)	$    9,802		$  13,636		$    8,985		$           —		$      (656)

 

3.     The adjusted tax rate for the full-year 2025 was 18.0 percent, as detailed below:
	Twelve Months Ended December 31, 2025
(dollars in millions)	Pre-tax earnings		Income taxes		Tax rate
As reported (GAAP)	$             6,597		$             2,364		35.8 %
Specified items	15,095		1,537		10.2 %
As adjusted (non-GAAP)	$           21,692		$             3,901		18.0 %

 

AbbVie Inc. Reconciliation of GAAP Reported to Non-GAAP Adjusted Information (Unaudited)
1.     Specified items impacted results as follows:
	Twelve Months Ended December 31, 2024
(in millions, except per share data)	Earnings				Diluted
	Pre-tax		After-taxa		EPS
As reported (GAAP)	$              3,716		$              4,278		$                2.39
Adjusted for specified items:
Intangible asset amortization	7,622		6,461		3.63
Intangible asset impairment	4,476		3,512		1.98
Acquisition and integration costs	1,061		978		0.55
Change in fair value of contingent consideration	3,771		3,673		2.07
Litigation matters	910		721		0.41
Income tax items	—		(1,819)		(1.02)
Other	256		197		0.11
As adjusted (non-GAAP)	$           21,812		$           18,001		$              10.12
a Represents net earnings attributable to AbbVie Inc. Specified items reflect the impact of applicable statutory tax rates.
Intangible asset impairment reflects a partial after-tax impairment charge of $3.5 billion related to the emraclidine intangible asset acquired as part of the Cerevel Therapeutics acquisition. Acquisition and integration costs primarily reflect costs related to the ImmunoGen and Cerevel Therapeutics acquisitions. Income tax items primarily reflect an income tax benefit related to the settlement of income tax examinations, partially offset by changes in income tax reserves. Litigation matters primarily include charges related to actual and potential settlements of litigation.
Reported GAAP earnings and adjusted non-GAAP earnings for the twelve months ended December 31, 2024 included acquired IPR&D and milestones expense of $2.8 billion on a pre-tax and $2.7 billion on an after-tax basis, representing an unfavorable impact of $1.52 to both diluted EPS and adjusted diluted EPS.

 

2.     The impact of the specified items by line item was as follows:
	Twelve Months Ended December 31, 2024
(in millions)	Cost of products sold		SG&A		R&D		Other operating income		Interest expense, net		Other expense, net
As reported (GAAP)	$  16,904		$  14,752		$  12,791		$           (7)		$    2,160		$    3,240
Adjusted for specified items:
Intangible asset amortization	(7,622)		—		—		—		—		—
Intangible asset impairment	—		—		(4,476)		—		—		—
Acquisition and integration costs	(225)		(554)		(258)		—		(24)		—
Change in fair value of contingent consideration	—		—		—		—		—		(3,771)
Litigation matters	—		(910)		—		—		—		—
Other	(110)		(54)		(1)		7		—		(98)
As adjusted (non-GAAP)	$    8,947		$  13,234		$    8,056		$           —		$    2,136		$      (629)

 

3.     The adjusted tax rate for the full-year 2024 was 17.4 percent, as detailed below:
	Twelve Months Ended December 31, 2024
(dollars in millions)	Pre-tax earnings		Income taxes		Tax rate
As reported (GAAP)	$             3,716		$               (570)		(15.3) %
Specified items	18,096		4,373		24.2 %
As adjusted (non-GAAP)	$           21,812		$             3,803		17.4 %

 

View original content:https://www.prnewswire.com/news-releases/abbvie-reports-full-year-and-fourth-quarter-2025-financial-results-302678316.html

SOURCE AbbVie

FAQ

What were AbbVie (ABBV) full-year 2025 revenues and EPS?

AbbVie reported full-year 2025 net revenues of $61.160 billion and GAAP diluted EPS of $2.36. According to the company, adjusted diluted EPS was $10.00, which includes a $2.76 per-share impact from acquired IPR&D and milestones.

How did AbbVie's (ABBV) immunology drugs perform in 2025?

AbbVie's immunology portfolio generated $30.406 billion in 2025, up 14.0% reported. According to the company, Skyrizi reached $17.562 billion and Rinvoq $8.304 billion, driving the division's growth.

What guidance did AbbVie (ABBV) give for 2026 adjusted diluted EPS?

AbbVie provided 2026 adjusted diluted EPS guidance of $14.37 to $14.57. According to the company, this range excludes any potential acquired IPR&D and milestones expense that may occur in 2026.

What were AbbVie's (ABBV) fourth-quarter 2025 results and key drivers?

AbbVie's Q4 2025 net revenues were $16.618 billion and adjusted diluted EPS was $2.71. According to the company, strong Skyrizi and Rinvoq sales and growth in neuroscience brands supported quarterly performance.

Did AbbVie (ABBV) report any notable regulatory or business developments in 2025?

Yes. According to the company, FDA approved Epkinly in combination with R2 for relapsed/refractory follicular lymphoma and AbbVie submitted Rinvoq and Aquipta filings to regulators for new indications.